Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
Cartherics to present at Australia Biologics Festival 2024
By Christine Filippis / January 23, 2024
Cartherics is pleased to announce that Dr Ian Nisbet, Chief Operating Officer, will be presenting at Australia Biologics 2024 at...
Read More
Buoyant Life Sciences Sector Emerges Stronger
By Christine Filippis / December 18, 2023
BioSpectrum Asia’s cover story in its December edition reflects on the advancement and changes that have shaped the industry in...
Read More
Chimeric Antigen Receptor (CAR) – Natural Killer (NK) Cells – Looking good for cancer therapy
By Christine Filippis / November 28, 2023
As published in Drug Target Review Professor Alan Trounson, AO Dr Huimin Cao Dr Aleta Pupovac The suitability of NK...
Read More
